Interactive Drug Benefit List
Date Listed/Coverage Update:
01-Jun-2013
Unit Price:
4.1016
LCA Price:
1.2692
MAC Price:
N/A
Unit of Issue:
Tablet
Manufacturer:
OTSUKA CANADA PHARMACEUTICAL INC. (OTS)
ATC:
N05AX12
Provincial Drug Schedule:
1
Interchangeable Products:
Yes
Coverage Status:
REGULAR BENEFIT/RESTRICTED BENEFIT
Applies to Clients of:
Non-Group Coverage (Group 1) Coverage for Seniors (Group 66) Palliative Coverage (Group 20514, Please note your client may have Group 1 or Group 66 coverage) Child and Family Services (Group 20403) Alberta Child Health Benefit (Group 20400) Children and Youth Services (Group 19824) Income Support (Group 19823) Alberta Human Services (AISH) (Group 19823) Alberta Adult Health Benefit (AAHB) (Group 23609)
Special Authorization Request Form:
N/A
Coverage Criteria:
ALBERTA HUMAN SERVICES RESTRICTED BENEFIT RESTRICTED BENEFIT - This product is a benefit for Alberta Human Services clients 13 years of age and older.
Review Status / Past Decisions
Indication
Reviewing Body
Submission Completion Date
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
CDR Recommendation
Review Status
MAJOR DEPRESSIVE DISORDER
Common Drug Review
2013/10/08
2015/04/01
No Change in Benefit Status
MAJOR DEPRESSIVE DISORDER
Common Drug Review
2013/10/08
2014/10/22
View
CDR - Do not list
MAJOR DEPRESSIVE DISORDER
Common Drug Review
2013/10/08
2015/04/01
No Change in Benefit Status
MAJOR DEPRESSIVE DISORDER
Common Drug Review
2013/10/08
2014/10/22
View
CDR - Do not list
N/A
Expert Committee
2013/06/14
2013/09/01
Under Review
N/A
Expert Committee
2013/06/14
2013/11/01
No Change in Benefit Status
N/A
Expert Committee
2013/06/14
2013/09/01
Under Review
N/A
Expert Committee
2013/06/14
2013/11/01
No Change in Benefit Status
N/A
Expert Committee
2012/10/15
2013/03/01
Under Review
N/A
Expert Committee
2012/10/15
2013/02/01
Under Review
N/A
Expert Committee
2012/10/15
2013/06/01
Regular Benefit
N/A
Expert Committee
2012/10/15
2013/03/01
Under Review
N/A
Expert Committee
2012/10/15
2013/02/01
Under Review
N/A
Expert Committee
2012/10/15
2013/06/01
Regular Benefit
SCHIZOPHRENIA AND RELATED PSYCHOTIC DISORDERS
Common Drug Review
2011/04/12
2011/11/01
Under Review
SCHIZOPHRENIA AND RELATED PSYCHOTIC DISORDERS
Common Drug Review
2011/04/12
2011/07/18
View
CDR - List with criteria/condition
SCHIZOPHRENIA AND RELATED PSYCHOTIC DISORDERS
Common Drug Review
2011/04/12
2012/01/01
Regular Benefit
SCHIZOPHRENIA AND RELATED PSYCHOTIC DISORDERS
Common Drug Review
2011/04/12
2011/11/01
Under Review
SCHIZOPHRENIA AND RELATED PSYCHOTIC DISORDERS
Common Drug Review
2011/04/12
2011/07/18
View
CDR - List with criteria/condition
SCHIZOPHRENIA AND RELATED PSYCHOTIC DISORDERS
Common Drug Review
2011/04/12
2012/01/01
Regular Benefit
N/A
Expert Committee
2010/10/14
2011/02/01
Not a Benefit
N/A
Expert Committee
2010/10/14
2011/02/01
Not a Benefit
SCHIZOPHRENIA
Common Drug Review
2009/11/13
2010/07/20
Not a Benefit
SCHIZOPHRENIA
Common Drug Review
2009/11/13
2010/04/27
View
CDR - Do not list
SCHIZOPHRENIA
Common Drug Review
2009/11/13
2010/07/20
Not a Benefit
SCHIZOPHRENIA
Common Drug Review
2009/11/13
2010/04/27
View
CDR - Do not list
Please select one
No Change in Benefit Status
CDR - Do not list
No Change in Benefit Status
CDR - Do not list
Under Review
No Change in Benefit Status
Under Review
No Change in Benefit Status
Under Review
Under Review
Regular Benefit
Under Review
Under Review
Regular Benefit
Under Review
CDR - List with criteria/condition
Regular Benefit
Under Review
CDR - List with criteria/condition
Regular Benefit
Not a Benefit
Not a Benefit
Not a Benefit
CDR - Do not list
Not a Benefit
CDR - Do not list
Indication
MAJOR DEPRESSIVE DISORDER
Reviewing Body
Common Drug Review
Submission Completion Date
2013/10/08
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
2015/04/01
CDR Recommendation
Review Status
No Change in Benefit Status
Indication
MAJOR DEPRESSIVE DISORDER
Reviewing Body
Common Drug Review
Submission Completion Date
2013/10/08
CDR Recommendation Date
2014/10/22
Expert Committee Recommendation Date
ADBL Effective Date
CDR Recommendation
View
Review Status
CDR - Do not list
Indication
MAJOR DEPRESSIVE DISORDER
Reviewing Body
Common Drug Review
Submission Completion Date
2013/10/08
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
2015/04/01
CDR Recommendation
Review Status
No Change in Benefit Status
Indication
MAJOR DEPRESSIVE DISORDER
Reviewing Body
Common Drug Review
Submission Completion Date
2013/10/08
CDR Recommendation Date
2014/10/22
Expert Committee Recommendation Date
ADBL Effective Date
CDR Recommendation
View
Review Status
CDR - Do not list
Indication
N/A
Reviewing Body
Expert Committee
Submission Completion Date
2013/06/14
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
2013/09/01
CDR Recommendation
Review Status
Under Review
Indication
N/A
Reviewing Body
Expert Committee
Submission Completion Date
2013/06/14
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
2013/11/01
CDR Recommendation
Review Status
No Change in Benefit Status
Indication
N/A
Reviewing Body
Expert Committee
Submission Completion Date
2013/06/14
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
2013/09/01
CDR Recommendation
Review Status
Under Review
Indication
N/A
Reviewing Body
Expert Committee
Submission Completion Date
2013/06/14
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
2013/11/01
CDR Recommendation
Review Status
No Change in Benefit Status
Indication
N/A
Reviewing Body
Expert Committee
Submission Completion Date
2012/10/15
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
2013/03/01
CDR Recommendation
Review Status
Under Review
Indication
N/A
Reviewing Body
Expert Committee
Submission Completion Date
2012/10/15
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
2013/02/01
CDR Recommendation
Review Status
Under Review
Indication
N/A
Reviewing Body
Expert Committee
Submission Completion Date
2012/10/15
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
2013/06/01
CDR Recommendation
Review Status
Regular Benefit
Indication
N/A
Reviewing Body
Expert Committee
Submission Completion Date
2012/10/15
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
2013/03/01
CDR Recommendation
Review Status
Under Review
Indication
N/A
Reviewing Body
Expert Committee
Submission Completion Date
2012/10/15
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
2013/02/01
CDR Recommendation
Review Status
Under Review
Indication
N/A
Reviewing Body
Expert Committee
Submission Completion Date
2012/10/15
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
2013/06/01
CDR Recommendation
Review Status
Regular Benefit
Indication
SCHIZOPHRENIA AND RELATED PSYCHOTIC DISORDERS
Reviewing Body
Common Drug Review
Submission Completion Date
2011/04/12
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
2011/11/01
CDR Recommendation
Review Status
Under Review
Indication
SCHIZOPHRENIA AND RELATED PSYCHOTIC DISORDERS
Reviewing Body
Common Drug Review
Submission Completion Date
2011/04/12
CDR Recommendation Date
2011/07/18
Expert Committee Recommendation Date
ADBL Effective Date
CDR Recommendation
View
Review Status
CDR - List with criteria/condition
Indication
SCHIZOPHRENIA AND RELATED PSYCHOTIC DISORDERS
Reviewing Body
Common Drug Review
Submission Completion Date
2011/04/12
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
2012/01/01
CDR Recommendation
Review Status
Regular Benefit
Indication
SCHIZOPHRENIA AND RELATED PSYCHOTIC DISORDERS
Reviewing Body
Common Drug Review
Submission Completion Date
2011/04/12
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
2011/11/01
CDR Recommendation
Review Status
Under Review
Indication
SCHIZOPHRENIA AND RELATED PSYCHOTIC DISORDERS
Reviewing Body
Common Drug Review
Submission Completion Date
2011/04/12
CDR Recommendation Date
2011/07/18
Expert Committee Recommendation Date
ADBL Effective Date
CDR Recommendation
View
Review Status
CDR - List with criteria/condition
Indication
SCHIZOPHRENIA AND RELATED PSYCHOTIC DISORDERS
Reviewing Body
Common Drug Review
Submission Completion Date
2011/04/12
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
2012/01/01
CDR Recommendation
Review Status
Regular Benefit
Indication
N/A
Reviewing Body
Expert Committee
Submission Completion Date
2010/10/14
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
2011/02/01
CDR Recommendation
Review Status
Not a Benefit
Indication
N/A
Reviewing Body
Expert Committee
Submission Completion Date
2010/10/14
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
2011/02/01
CDR Recommendation
Review Status
Not a Benefit
Indication
SCHIZOPHRENIA
Reviewing Body
Common Drug Review
Submission Completion Date
2009/11/13
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
2010/07/20
CDR Recommendation
Review Status
Not a Benefit
Indication
SCHIZOPHRENIA
Reviewing Body
Common Drug Review
Submission Completion Date
2009/11/13
CDR Recommendation Date
2010/04/27
Expert Committee Recommendation Date
ADBL Effective Date
CDR Recommendation
View
Review Status
CDR - Do not list
Indication
SCHIZOPHRENIA
Reviewing Body
Common Drug Review
Submission Completion Date
2009/11/13
CDR Recommendation Date
Expert Committee Recommendation Date
ADBL Effective Date
2010/07/20
CDR Recommendation
Review Status
Not a Benefit
Indication
SCHIZOPHRENIA
Reviewing Body
Common Drug Review
Submission Completion Date
2009/11/13
CDR Recommendation Date
2010/04/27
Expert Committee Recommendation Date
ADBL Effective Date
CDR Recommendation
View
Review Status
CDR - Do not list
GLOSSARY
Telephone:
(514) 332-3001
Toll-Free:
(888) 997-9017
To return to the printable Drug Benefit List and related publications,
click here
The DBL, DBS and related publications require knowledgeable interpretation and are intended primarily for professional health care practitioners, pharmacies, hospitals and organizations associated with the manufacture, distribution and use of pharmaceutical preparations.
Electronic versions of all DBL and DBS related publications are unofficial versions and are provided for convenience and private use only. Official paper versions can be obtained from Alberta Blue Cross who publishes them on behalf of Alberta Health and Alberta Human Services.
Alberta Health reserves the right to make changes, without notice, to the List through the Interactive DBL(iDBL) , and any such changes to the Interactive DBL(iDBL) are effective the date of the change (unless otherwise stated) and regardless of the date of publication in the paper version or updates.